LifeSpan and MBL Announce Multi-Year Licensing and Asset Agreement
News Feb 22, 2006
LifeSpan BioSciences, Inc. and MBL International Corporation, a wholly owned subsidiary of Medical and Biological Laboratories Co., Ltd. (Nagoya, Japan), have announced a multi-year relationship in which MBLI will distribute antibodies to druggable gene targets that LifeSpan has developed and commercialized.
As part of the new relationship, MBLI has purchased LifeSpan’s existing inventory of 900 antibodies including the exclusive research reagent sales rights.
Dennis Walczewski, chief executive officer of MBLI said, "The relationship with LifeSpan addresses the needs of both organizations."
"The products and technology obtained from LifeSpan complement our existing product lines, increasing our product offering to over 4,000 products. LifeSpan and MBLI feel that this relationship will help both companies meet the future needs of the scientific research community."
Dr. Joseph Brown, president and CEO of LifeSpan said, "This partnership with MBLI is an important milestone in LifeSpan’s long term strategy to become a global provider of Molecular Pathology products and services, including reagent antibodies to the genes most important in finding new treatments for disease."
"Moreover, it gives LifeSpan new resources to fund additional development within our core business."
A new discovery about dangerous C. difficile diarrhea has identified a new way that the bacteria – and possibly others like it – cause severe disease. C. diff is the most common hospital-acquired infection and estimated to result in 453,000 cases per year, with 29,300 associated deaths.READ MORE